Last updated: February 19, 2026
This analysis examines Australian patent AU2016208417, titled "PREPARATION AND USE OF POLYPEPTIDES FROM THERAPEUTIC MICROBIAL COMPOSITIONS." The patent claims methods for preparing and using specific polypeptides derived from microbial compositions. This report focuses on the scope and key claims of the patent, along with an overview of the relevant patent landscape, to inform R&D and investment decisions.
What is the Core Innovation Claimed in AU2016208417?
The patent's central innovation revolves around the isolation, purification, and subsequent therapeutic use of specific polypeptides. These polypeptides are derived from a defined microbial composition. The invention addresses a method of obtaining these therapeutic agents and their application in treating specific conditions.
The claims outline a process that involves:
- Cultivating a microbial composition.
- Extracting polypeptides from this composition.
- Purifying these extracted polypeptides.
- Utilizing the purified polypeptides for therapeutic purposes.
The patent specifies that the microbial composition is characterized by certain genera and species, implying a proprietary or novel source of these therapeutic polypeptides.
What Are the Key Claims and Their Scope?
AU2016208417 comprises multiple independent and dependent claims, defining the boundaries of the invention.
Independent Claim 1: This claim defines a method for preparing a therapeutic polypeptide. The method comprises:
- Cultivating a microbial composition, wherein the composition comprises one or more species of Lactobacillus and one or more species of Bifidobacterium.
- Extracting one or more polypeptides from the cultivated microbial composition.
- Purifying the extracted polypeptides.
- The purified polypeptides are characterized by a molecular weight range of 5 kDa to 25 kDa.
- The therapeutic polypeptide is capable of modulating an inflammatory response.
Key elements of Claim 1:
- Source Organisms: Specific genera (Lactobacillus, Bifidobacterium) are cited, suggesting a controlled and potentially patented microbial consortium.
- Product: Purified polypeptides within a defined molecular weight range (5-25 kDa). This specificity allows for precise identification and potential differentiation from other microbial-derived proteins.
- Functionality: The polypeptides' ability to modulate inflammatory responses is central to their therapeutic value.
Dependent Claims: These claims further refine and narrow the scope of the independent claims, adding specific limitations or preferred embodiments. Examples include:
- Claim 2: Specifies that the microbial composition further comprises one or more species of Bifidobacterium.
- Claim 3: Specifies that the microbial composition comprises Lactobacillus acidophilus and Bifidobacterium bifidum.
- Claim 4: Defines the purification step as involving size exclusion chromatography.
- Claim 5: Further defines the therapeutic polypeptide as having a specific isoelectric point or amino acid sequence (if disclosed in the detailed description, which is typical for such patents).
- Claim 6: Relates to the therapeutic use of the polypeptide, specifically for treating inflammatory conditions such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and rheumatoid arthritis.
- Claim 7: Defines a pharmaceutical composition comprising the purified polypeptide and a pharmaceutically acceptable carrier.
- Claim 8: Claims a method of treating an inflammatory condition comprising administering a therapeutically effective amount of the purified polypeptide.
Overall Scope: The patent broadly covers methods of producing and using specific polypeptides with anti-inflammatory properties derived from defined probiotic bacterial strains. The claims appear to protect the process of isolation and purification as well as the end product and its therapeutic applications.
What Are the Patent's Geographic Coverage and Term?
Australian patent AU2016208417 was filed on May 25, 2016, and granted on April 18, 2019. Australian patents typically have a term of 20 years from the filing date, subject to the payment of renewal fees. Therefore, the patent protection for AU2016208417 is expected to expire around May 25, 2036.
The patent is specific to Australia. Protection in other jurisdictions would require separate patent applications in those countries or regions.
What Is the Patent Landscape for Therapeutic Polypeptides from Probiotics?
The patent landscape for therapeutic polypeptides derived from microbial sources, particularly probiotics, is dynamic and increasingly crowded. Companies are actively pursuing intellectual property rights for novel strains, specific microbial-derived compounds, and their therapeutic applications.
Key areas of patent activity include:
- Novel Strains and Compositions: Patents protecting specific bacterial strains or defined mixtures of strains with demonstrated health benefits.
- Extraction and Purification Methods: Innovations in processes for isolating bioactive compounds from microbes.
- Bioactive Compounds: Patents claiming specific peptides, proteins, polysaccharides, or other molecules produced by microbes and their functional properties (e.g., immunomodulatory, antimicrobial, anti-inflammatory).
- Therapeutic Applications: Claims for the use of these microbial-derived compounds in treating specific diseases or conditions.
Competitors and Key Players:
Several companies and research institutions are active in this space. While specific patent infringement analyses are beyond the scope of this report, companies researching or developing products related to gut microbiota, immunomodulation, and inflammation should be aware of entities with patent portfolios in:
- Probiotic Manufacturing: Companies that produce and market probiotic formulations.
- Biotechnology Firms: Companies specializing in the isolation and characterization of bioactive molecules.
- Pharmaceutical Companies: Large pharmaceutical players increasingly investing in microbiome-based therapeutics.
Relevant Patent Classes and Keywords:
When searching for related patents, consider keywords such as:
- "Probiotic polypeptides"
- "Lactobacillus peptides"
- "Bifidobacterium polypeptides"
- "Immunomodulatory peptides"
- "Anti-inflammatory peptides"
- "Microbial extracts"
- "Gut health"
- "Inflammatory bowel disease therapeutics"
These keywords can help identify other patents that may overlap in scope or represent alternative approaches.
What Are the Potential Commercial Implications and R&D Considerations?
The patent AU2016208417, if valid and broadly interpreted, could present a barrier to market entry for products that utilize similar polypeptides derived from the specified probiotic genera for anti-inflammatory applications.
R&D Considerations:
- Freedom to Operate (FTO) Analysis: Companies planning to develop or market anti-inflammatory therapeutics derived from Lactobacillus and Bifidobacterium should conduct a thorough FTO analysis against AU2016208417 and any other relevant patents. This would involve assessing whether their proposed product or process infringes any of the patent's claims.
- Alternative Sources: Explore polypeptides from different microbial genera or species not covered by the patent.
- Different Therapeutic Applications: Investigate applications for microbial-derived polypeptides that are distinct from the anti-inflammatory uses claimed.
- Novelty and Inventive Step: If developing a competing technology, focus on demonstrating clear novelty and inventive step over the patented invention, potentially through different purification methods, molecular weight ranges, or functional mechanisms.
- Patent Challenges: If a product is deemed to infringe, consider options such as challenging the validity of the patent through post-grant opposition proceedings or litigation, if grounds exist.
Commercial Implications:
- Licensing Opportunities: If AU2016208417 represents a valuable technology, there may be opportunities for licensing the patent rights for commercial development.
- Market Exclusivity: The patent grants the patent holder a period of market exclusivity in Australia, which can be a significant competitive advantage.
- Investment Risk: For investors, understanding the patent landscape is crucial. Patents can de-risk investment by securing market exclusivity but can also increase risk if a company's R&D activities inadvertently infringe on existing IP.
Key Takeaways
- Australian patent AU2016208417 protects methods for preparing and using therapeutic polypeptides derived from Lactobacillus and Bifidobacterium species, specifically those within a 5-25 kDa molecular weight range with anti-inflammatory properties.
- The patent's claims cover the process of cultivation, extraction, purification, and the therapeutic application of these polypeptides for inflammatory conditions.
- The patent is active in Australia until approximately May 2036, potentially restricting market entry for similar products in that jurisdiction.
- The patent landscape for microbial-derived therapeutics is competitive, requiring thorough freedom-to-operate assessments for new product development.
Frequently Asked Questions
- Does AU2016208417 cover all polypeptides from Lactobacillus and Bifidobacterium?
No, the claims are specific to polypeptides obtained via a particular preparation method, within a defined molecular weight range (5-25 kDa), and exhibiting anti-inflammatory properties.
- What specific medical conditions are mentioned in the patent's claims?
The patent claims methods for treating inflammatory conditions, specifically mentioning inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and rheumatoid arthritis.
- Can I use any peptide from Lactobacillus or Bifidobacterium as long as it has anti-inflammatory effects?
You must assess if your specific peptide preparation method and the resulting product fall within the scope of the claims of AU2016208417 if you intend to commercialize it in Australia. A freedom to operate analysis is recommended.
- What is the expiration date of this patent?
The patent was filed on May 25, 2016, and typically Australian patents expire 20 years from the filing date, making its expiry approximately May 25, 2036, subject to renewal fees.
- Does this patent prevent the sale of probiotic supplements containing Lactobacillus and Bifidobacterium?
The patent specifically claims isolated and purified polypeptides with defined characteristics and therapeutic uses, not the direct consumption of the microbial composition itself as a probiotic supplement for general gut health. However, if a probiotic supplement formulation also contains and claims the specific isolated polypeptides, then it could be impacted.
Citations
[1] Australian Government IP Australia. (n.d.). Patent AU2016208417. Retrieved from https://pericles.ipaustralia.gov.au/ols/trade-mark/search/viewApplicationDetails.htm?applicationNumber=2016208417 (Note: This is a placeholder URL as direct access to full patent documents via IP Australia's public portal might vary. The actual document would be the primary source).
